Friday, August 5, 2016

UPDATE 2-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge

Aug 5 (Reuters) - Bristol-Myers Squibb Co said its

blockbuster Opdivo immunotherapy failed to slow progression of

symptoms in previously untreated patients with advanced lung

cancer in a late-stage...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)